---
title: "TEVA: Innovative product growth and biosimilars drive raised outlook and strong cash flow in Q2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294226672.md"
description: "Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the Emalex acquisition and biosimilars expansion support long-term growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-29T14:59:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294226672.md)
  - [en](https://longbridge.com/en/news/294226672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294226672.md)
generator: "portal-rs"
---

# TEVA: Innovative product growth and biosimilars drive raised outlook and strong cash flow in Q2 2026

Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the Emalex acquisition and biosimilars expansion support long-term growth.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Teva's patent and communications strategies in Turkey face probe](https://longbridge.com/en/news/297043765.md)
- [Teva Chief Accounting Officer Amir Weiss sells 9,445 shares for $355,291.07](https://longbridge.com/en/news/297014903.md)
- [Quest Diagnostics teams with Humanity to offer biological age analysis on Questhealth.com](https://longbridge.com/en/news/296926398.md)
- [Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA](https://longbridge.com/en/news/296924113.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**